ExpreS2ion Biotech: Updated phase I immunogenicity data - Redeye

Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-targeting cancer vaccine candidate ES2B-C001. The company reports early signs of vaccine-specific immune responses in five out of six evaluable patients, alongside continued favourable safety observations. While the dataset remains limited, we view the update as supportive of the program’s scientific rationale and development trajectory, with several clinical milestones expected throughout 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1146897/expres2ion-biotech-updated-phase-i-immunogenicity-data?utm_source=finwire&utm_medium=RSS